Skip to main content

Press releases | January 19, 2022

Fried Frank counseled BofA Securities and SVB Leerink as financial advisors to Zogenix, Inc., a U.S.-based manufacturer of drugs that treat seizures and rare diseases, in its US$1.9 billion acquisition by Belgian pharmaceutical company UCB SA (UCB). The transaction will expand UCB's portfolio of drug and treatment targets to include epilepsy.

Corporate partners Philip Richter and Roy Tannenbaum and corporate law clerk Trent Pacer advised BofA Securities and corporate partner Warren S. de Wied advised SVB Leerink.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.